http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2757590-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79ae6dd5bafbd2dd69035367385d754c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-04 |
| filingDate | 2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63b8ef461c3a2917493b495bc9fd8016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca74282e65558cc05ec58bef3aa9dc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92f1183baa53d852c70adc88ff9c2781 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b5f1637c8d94f391dda733723f0b9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd7677babc841ddf4e8b9512bcf49be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af77f8bbd61da40a217f8ef24ff84213 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7bc1a776ac1e211964e0068d0343088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f1e8c99f7dd6f7a90e6a7f52392ca2 |
| publicationDate | 2021-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2757590-C1 |
| titleOfInvention | Method for determining the prognosis of the effectiveness of breast cancer therapy |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to oncology, and is intended to predict the effectiveness of neoadjuvant chemotherapy for breast cancer. The patient's non-fixed tumor tissue is harvested using a core-biopsy method. Tumor-infiltrating lymphocytes (TIL) with a subpopulation of lymphocytes are quantified by flow cytometry with their verification by light microscopy with counting the number of lymphoid cells in 10 fields of view. Subpopulations of TIL CD45+/CD14- и CD3-CD19+. are determined. The level of expression of the intracellular marker Ki67 and the progesterone receptor (PR) is determined. The HER2 marker is determoned. At a concentration of CD45+/CD14- cells ≥ 4,3%, CD3-CD19+ cells ≤ 4%, Ki67 positive cells ≤ 50%, the absence of HER2 expression on tumor cells and a concentration of PR positive cells ≤10% the effectiveness of neoadjuvant chemotherapy is predicted.EFFECT: invention provides for the determination of the prognosis of the efficacy of the neoadjuvant therapy option intended to be administered in a particular patient on the basis of the qualitative and quantitative characteristics of TIL and their subpopulation.1 cl, 2 dwg, 1 tbl, 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2771760-C1 |
| priorityDate | 2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.